Artificial T-cell receptors provide enhanced ability to T-cells for targeting a specific protein. These receptors are often called as Chimeric Antigen Receptor (CAR) or Chimeric T-Cell Receptor which are bound to surface of T-cells and serve the purpose of alerting immune systems about the impending virus attack. The artificial T-cell receptors market is expected to grow at an impressive growth rate over the forecast period. A major factor that augments the growth of the market is the rising prevalence of cancer disease across the globe. Moreover, increasing incidence of immunological diseases and chronic diseases such as cardiovascular diseases across the globe is further fueling the market growth.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/artificial-t-cell-receptors-market
Significant prevalence of cancer disease has been observed in the US. According to the American Cancer Society in 2017, it was estimated that out of total 600,920 cancer deaths in the US, around 190,500 would be caused by cigarette smoking. In addition, it was estimated by the World Cancer Research Fund that 20% of cancers are caused by factors such as physical inactivity, excess body weight, excess alcohol consumption, and poor nutrition. Moreover, as per American Cancer Society in 2017, 87% of all the cancers in the US were diagnosed in people with age 50 years and above. However, these cancers were preventable. Additionally, colorectal and cervical cancers can be prevented by screening and by removal of precancerous lesions. Screening also has reduced the mortality rate significantly for the cancers of colon, breast, and lung. These facts and figures reflect the need for less-toxic forms of immune-based cellular therapy such as T-cell receptors therapy to treat cancer which ultimately results in positive market growth.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/artificial-t-cell-receptors-market
Geographically, the market is divided into North America, Europe, Asia-Pacific and Rest of the World. North America region is growing with significant growth and is expected to dominate the global artificial T-cell receptors market. The growth is attributed to the increasing number of cancer patients and extensive cell-based research in the region. Moreover, the presence of key players that uses artificial T-cell receptors for the development of new drugs and therapy is further supporting the market growth in the region. Europe is the expected to follow North America in terms of revenue generation due to the technological advancements in the biotechnology field. Furthermore, Asia-Pacific is considered as the fastest growing market during the forecast period. A rapidly aging population coupled with the growing number of cancer patients and high penetration of new technology are the key factors for the growth of the artificial T-cell receptors market in Asia-Pacific region.
Market Segmentation
Global Artificial T-Cell Receptors Market by Disease
Cancer
- Acute Lymphoblastic Leukemia (ALL)
- Diffuse Large B-Cell Lymphoma
- Other Cancer Types
Immunological Disorders
Global Artificial T-Cell Receptors Market by Therapy
- Autologous
- Allogenic
Global Artificial T-Cell Receptors Market by End-User
- Research Institutes
- Hospitals
- Biotech Companies
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
Rest of the World
Company Profiles
- Adaptive Biotechnologies Corp.
- Athenex, Inc.
- Blubird Bio, Inc.
- Cabaletta Bio, Inc.
- Celgene Corp.
- Cell Medica Ltd.
- Eli Lilly & Co.
- Juno Therapeutics, Inc.
- Kite Pharma, Inc.
- Lonza Group Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
